SG145717A1 - Composition for releasing a weak base for an extended period of time - Google Patents
Composition for releasing a weak base for an extended period of timeInfo
- Publication number
- SG145717A1 SG145717A1 SG200805824-0A SG2008058240A SG145717A1 SG 145717 A1 SG145717 A1 SG 145717A1 SG 2008058240 A SG2008058240 A SG 2008058240A SG 145717 A1 SG145717 A1 SG 145717A1
- Authority
- SG
- Singapore
- Prior art keywords
- composition
- weak base
- releasing
- dosage form
- time
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49338803P | 2003-08-07 | 2003-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG145717A1 true SG145717A1 (en) | 2008-09-29 |
Family
ID=34135242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200805824-0A SG145717A1 (en) | 2003-08-07 | 2004-08-06 | Composition for releasing a weak base for an extended period of time |
Country Status (25)
Country | Link |
---|---|
US (1) | US20070134326A1 (es) |
EP (1) | EP1660049A2 (es) |
JP (1) | JP2007501773A (es) |
KR (1) | KR20060113650A (es) |
CN (2) | CN1832729A (es) |
AP (1) | AP2006003488A0 (es) |
AR (1) | AR045330A1 (es) |
AU (1) | AU2004262926B2 (es) |
BR (1) | BRPI0413374A (es) |
CA (1) | CA2534546A1 (es) |
EA (2) | EA011508B1 (es) |
EC (1) | ECSP066318A (es) |
IL (1) | IL173176A0 (es) |
IS (1) | IS8336A (es) |
MA (1) | MA27980A1 (es) |
MX (1) | MXPA06001407A (es) |
NO (1) | NO20061018L (es) |
NZ (1) | NZ544696A (es) |
OA (1) | OA13230A (es) |
PE (1) | PE20050335A1 (es) |
SG (1) | SG145717A1 (es) |
TW (1) | TW200517127A (es) |
UY (1) | UY28457A1 (es) |
WO (1) | WO2005013935A2 (es) |
ZA (1) | ZA200600521B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0203296D0 (en) | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
WO2005051325A2 (en) * | 2003-11-25 | 2005-06-09 | Sb Pharmco Puerto Rico Inc. | Carvedilol compositions methods of treatment and delivery |
GB0502479D0 (en) * | 2005-02-07 | 2005-03-16 | Sb Pharmco Inc | Novel compositions |
GB0502475D0 (en) * | 2005-02-07 | 2005-03-16 | Sb Pharmco Inc | Novel compositions |
US20100323016A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
US20100323015A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
US8524278B2 (en) | 2009-02-13 | 2013-09-03 | Romark Laboratories L.C. | Controlled release pharmaceutical formulations of nitazoxanide |
AU2011208745B2 (en) | 2010-01-20 | 2013-11-14 | Glaxo Group Limited | Novel retigabine composition |
CN103948557A (zh) * | 2014-04-08 | 2014-07-30 | 闻晓光 | 一种新型控释片 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8820353D0 (en) * | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
FR2655266B1 (fr) * | 1989-12-05 | 1992-04-03 | Smith Kline French Lab | Compositions pharmaceutiques a base de cimetidine. |
IT1264517B1 (it) * | 1993-05-31 | 1996-09-24 | Ekita Investments Nv | Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati |
HU213407B (en) * | 1993-12-09 | 1997-06-30 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tablet with diffusive-osmotic release |
US5407687A (en) * | 1994-02-22 | 1995-04-18 | Glaxo Inc. | Ranitidine solid dosage form |
US5952509A (en) * | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
GB9619757D0 (en) * | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
US20020004515A1 (en) * | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
US20010049380A1 (en) * | 1997-06-18 | 2001-12-06 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and sulphonylurea |
US20020006939A1 (en) * | 1997-10-13 | 2002-01-17 | Smithkline Beecham P.L.C. | Use of thiazolidinediones for the treatment of hyperglycaemia |
US6099859A (en) * | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
DE69939485D1 (de) * | 1998-11-12 | 2008-10-16 | Smithkline Beecham Plc | Arzneimittel zur gesteuerten freisetzung eines insulin sensibilisators und metformin |
AU2001257456B2 (en) * | 2000-05-01 | 2006-02-09 | Aeropharm Technology, Inc. | A core formulation |
GB0117618D0 (en) * | 2001-07-19 | 2001-09-12 | Phoqus Ltd | Pharmaceutical dosage form |
GB0127805D0 (en) * | 2001-11-20 | 2002-01-09 | Smithkline Beecham Plc | Pharmaceutical composition |
GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
PE20030800A1 (es) * | 2002-02-12 | 2003-10-31 | Glaxo Group Ltd | Forma de dosificacion oral de liberacion controlada |
-
2004
- 2004-08-05 UY UY28457A patent/UY28457A1/es not_active Application Discontinuation
- 2004-08-05 AR ARP040102794A patent/AR045330A1/es not_active Application Discontinuation
- 2004-08-05 PE PE2004000757A patent/PE20050335A1/es not_active Application Discontinuation
- 2004-08-05 TW TW093123415A patent/TW200517127A/zh unknown
- 2004-08-06 SG SG200805824-0A patent/SG145717A1/en unknown
- 2004-08-06 EA EA200600377A patent/EA011508B1/ru not_active IP Right Cessation
- 2004-08-06 CA CA002534546A patent/CA2534546A1/en not_active Abandoned
- 2004-08-06 CN CNA2004800226534A patent/CN1832729A/zh active Pending
- 2004-08-06 CN CNA2008100088784A patent/CN101239047A/zh active Pending
- 2004-08-06 US US10/567,146 patent/US20070134326A1/en not_active Abandoned
- 2004-08-06 EA EA200701409A patent/EA200701409A1/ru unknown
- 2004-08-06 NZ NZ544696A patent/NZ544696A/en unknown
- 2004-08-06 BR BRPI0413374-9A patent/BRPI0413374A/pt not_active Application Discontinuation
- 2004-08-06 JP JP2006522328A patent/JP2007501773A/ja not_active Withdrawn
- 2004-08-06 EP EP04763874A patent/EP1660049A2/en not_active Withdrawn
- 2004-08-06 MX MXPA06001407A patent/MXPA06001407A/es unknown
- 2004-08-06 OA OA1200600040A patent/OA13230A/en unknown
- 2004-08-06 AP AP2006003488A patent/AP2006003488A0/xx unknown
- 2004-08-06 KR KR1020067002663A patent/KR20060113650A/ko not_active Application Discontinuation
- 2004-08-06 AU AU2004262926A patent/AU2004262926B2/en not_active Ceased
- 2004-08-06 WO PCT/EP2004/008843 patent/WO2005013935A2/en active Application Filing
-
2006
- 2006-01-16 IL IL173176A patent/IL173176A0/en unknown
- 2006-01-18 ZA ZA200600521A patent/ZA200600521B/en unknown
- 2006-01-25 EC EC2006006318A patent/ECSP066318A/es unknown
- 2006-02-07 MA MA28777A patent/MA27980A1/fr unknown
- 2006-03-01 NO NO20061018A patent/NO20061018L/no not_active Application Discontinuation
- 2006-03-02 IS IS8336A patent/IS8336A/is unknown
Also Published As
Publication number | Publication date |
---|---|
OA13230A (en) | 2006-12-13 |
AP2006003488A0 (en) | 2006-02-28 |
AU2004262926A1 (en) | 2005-02-17 |
EA200701409A1 (ru) | 2007-10-26 |
US20070134326A1 (en) | 2007-06-14 |
ZA200600521B (en) | 2007-01-31 |
AR045330A1 (es) | 2005-10-26 |
MA27980A1 (fr) | 2006-07-03 |
CN101239047A (zh) | 2008-08-13 |
MXPA06001407A (es) | 2006-05-15 |
JP2007501773A (ja) | 2007-02-01 |
WO2005013935A3 (en) | 2005-07-14 |
PE20050335A1 (es) | 2005-06-01 |
IS8336A (is) | 2006-03-02 |
AU2004262926B2 (en) | 2009-11-19 |
ECSP066318A (es) | 2006-07-28 |
EP1660049A2 (en) | 2006-05-31 |
BRPI0413374A (pt) | 2006-10-17 |
NO20061018L (no) | 2006-03-01 |
IL173176A0 (en) | 2006-06-11 |
WO2005013935A2 (en) | 2005-02-17 |
KR20060113650A (ko) | 2006-11-02 |
NZ544696A (en) | 2009-03-31 |
CA2534546A1 (en) | 2005-02-17 |
EA011508B1 (ru) | 2009-04-28 |
EA200600377A1 (ru) | 2006-08-25 |
UY28457A1 (es) | 2005-03-31 |
TW200517127A (en) | 2005-06-01 |
CN1832729A (zh) | 2006-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA84266C2 (uk) | Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування | |
GEP20043324B (en) | Purine Derivatives | |
NO993520L (no) | Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon | |
GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
AP1818A (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | |
TW200500098A (en) | Methods and dosage forms for increasing solubility of drug compositions for controlled delivery | |
NZ516347A (en) | Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them | |
GEP20063895B (en) | Platinum derivative pharmaceutical formulations | |
TW200503775A (en) | Pharmaceutical composition and method for treating | |
ECSP066318A (es) | Composición para la liberación de una base debil por un periodo extendido de tiempo | |
HU229443B1 (en) | Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use | |
DE602004011966D1 (en) | Heterocyclylverbindungen | |
IL158668A0 (en) | Deuterated 3-piperidinopropiophenone and medicaments containing said compounds | |
GB0109122D0 (en) | Novel compounds | |
AP2003002763A0 (en) | Controlled release formulations for oral administration | |
HUP0203844A2 (hu) | Növekedési hormon kibocsátó tulajdonságú vegyület, ezt tartalmazó gyógyszerkészítmény és alkalmazása | |
TW200509992A (en) | Dosage form containing pantoprazole as active ingredient | |
TW200505436A (en) | Modified release pharmaceutical compositions and the processes for preparing them | |
TW200503785A (en) | Dosage form containing (S)-pantoprazole as active ingredient | |
AP1736A (en) | Oral dosage form for controlled drug release. | |
MXPA01012936A (es) | Composicion farmaceutica que contiene sibutramina y orlistat. | |
TW200510370A (en) | Urea derivatives | |
AU3278800A (en) | Pharmaceutical composition containing desoxypeganine for the treatment of drug dependence | |
ATE302010T1 (de) | Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus | |
TH78324B (th) | องค์ประกอบชนิดใหม่ |